Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled TrialsMegan E. B. Clowse, Daniel J. Wallace, Richard Furie et al.|Arthritis & Rheumatology|2016Cited by 237
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforceKathryn Connelly, Cristina Vazquez‐Mateo, Rangi Kandane‐Rathnayake et al.|Nature Reviews Rheumatology|2023Cited by 29
S15:02 Dapirolizumab pegol and flare reduction in patients with SLE in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practiceRichard Furie, C. Stach, George Bertsias et al.|Oral Presentations|2026Cited by 0